Chemagis Ltd.

Wavelength Enterprises Ltd

Perrigo Api Ltd.

Sonia Krivonos

Alex Weisman

Itai Adin

Gloria Ten Figas

Revital Ben-Daniel

Yevgeny Rozenblat

Lei Zhang

Ana Fernandez Casares

Yana Sery

Edna Danon

He Xungui

Liu Xing

Michel Bekhazi

Ana Fernadez Casares

Provided are ibrutinib polymorphs, e.g., crystalline ibrutinib Forms III, IV, V, VI, VII, VIII and Form IX and processes for producing these crystalline forms, stable amorphous ibrutinib and processes for preparing stable amorphous ibrutinib, pharmaceutical compositions comprising these forms and methods of using these crystalline and amorphous forms.

Ibrutinib solid forms and production process therefor

An isolated and pure crystalline rotigotine base of polymorph Form I, and processes for producing the crystalline rotigotine base are disclosed. Also disclosed is a transdermal patch for the delivery of rotigotine base using the disclosed isolated and pure form of rotigotine base, which can be used in treatment of Parkinson's Disease and other disorders ameliorated or treated by rotigotine, including restless leg syndrome.

Crystalline rotigotine base and preparation process therefor

Provided is a process for producing highly pure midazolam and salts thereof, and a pharmaceutical composition containing the highly pure midazolam and/or a salt thereof.

Process for producing highly pure midazolam and salts thereof

Provided is a process for producing imatinib and salts thereof, e.g., imatinib mesylate. The process includes reacting 4-(4-methyl-piperazin-1-ylmethyl)-benzoic acid with N-(5-amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidine-amine in the presence of a carboxylic acid coupling reagent, to produce imatinib, and optionally converting the imatinib into a salt.

Imatinib production process

Growing community of inventors

Beer Sheva, Israel

Sonia Krivonos